Skip to main content
Have a personal or library account? Click to login
Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma Cover

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma

Radiology and Oncology
Volume 49 (2015): Issue 4 (December 2015)
By:   
Open Access
|Nov 2015
References

References

  1. 1. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group.2002;221-30.
    Search in Google Scholar
  2. 2. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD.l 1997;528-34.
    Open DOISearch in Google Scholar
  3. 3. Radman I, Basić N, Labar B, Kovacević J, Aurer I, Bogdanić V, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin’s disease (Croatian experience).2002;1650-5.
    Open DOISearch in Google Scholar
  4. 4. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.1987;27-37.
    Open DOISearch in Google Scholar
  5. 5. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD.1992;1478-84.
    Open DOISearch in Google Scholar
  6. 6. Brice P. Managing relapsed and refractory Hodgkin lymphoma.2008;3-13.
    Open DOISearch in Google Scholar
  7. 7. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.2005;1473-8.
    Open DOISearch in Google Scholar
  8. 8. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J, et al. Treatment for primary refractory Hodgkin’s disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.2004;1225-9.
    Open DOISearch in Google Scholar
  9. 9. Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin’s lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).2006;283-8.
    Open DOISearch in Google Scholar
  10. 10. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.2013;410-7.
    Open DOISearch in Google Scholar
  11. 11. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma.2004;1015-23.
    Open DOISearch in Google Scholar
  12. 12. Puig N, Pintilie M, Seshadri T, Al-Farsi K, Nagy T, Franke N, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma.2010;1496-502.
    Open DOISearch in Google Scholar
  13. 13. Castagna L, Bramanti S, Balzarotti M, Sarina B, Todisco E, Anastasia A, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.2009;369-72.
    Open DOISearch in Google Scholar
  14. 14. Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.2014;39-52.
    Open DOISearch in Google Scholar
  15. 15. The National Comprehensive Cancer Network. NCCN Guidelines. [citated 2015 Jul 6]. Available at.
    Search in Google Scholar
  16. 16. Thomson KJ, Peggs KS, Blundell E, Goldstone AH, Linch DC. A second autologous transplant may be efficacious in selected patients with Hodgkin’s lymphoma relapsing after a previous autograft.2007;881-4.
    Open DOISearch in Google Scholar
  17. 17. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma.2012;2183-9.
    Open DOISearch in Google Scholar
  18. 18. Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease.1994;817-20.
    Open DOISearch in Google Scholar
  19. 19. Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.2013;456-60.
    Open DOISearch in Google Scholar
  20. 20. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.2012;4123-8.
    Open DOISearch in Google Scholar
  21. 21. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.2012;4129-32.
    Open DOISearch in Google Scholar
  22. 22. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.2010;320-4.
    Open DOISearch in Google Scholar
  23. 23. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma.2004;110-5.
    Open DOISearch in Google Scholar
  24. 24. Provencio M, Sánchez A, Sánchez-Beato M. New drugs and targeted treatments in Hodgkin’s lymphoma.2014;457-64.
    Open DOISearch in Google Scholar
  25. 25. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!2014;599-606.
    Search in Google Scholar
  26. 26. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study.2012;2197-203.
    Open DOISearch in Google Scholar
  27. 27. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma.2015;311-9.
    Open DOISearch in Google Scholar
  28. 28. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.2010;888-97.
    Open DOISearch in Google Scholar
  29. 29. eMC. Adcetris 50 mg powder for concentrate for solution for infusion. [citated 2015 Jul 6]. Available at.
    Search in Google Scholar
  30. 30. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.2012;6379-81.
    Open DOISearch in Google Scholar
  31. 31. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.2010;1812-21.
    Open DOISearch in Google Scholar
  32. 32. Gopal AK, Ramchandren R, O’Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.2012;560-8.
    Open DOISearch in Google Scholar
  33. 33. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.2012;1470-2.
    Open DOISearch in Google Scholar
  34. 34. Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.2012;1073-80.
    Open DOISearch in Google Scholar
  35. 35. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.2013;611-4.
    Open DOISearch in Google Scholar
  36. 36. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials.2013;1232-6.
    Open DOISearch in Google Scholar
  37. 37. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies.2012;248-55.
    Open DOISearch in Google Scholar
  38. 38. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.2015;1236-43.
    Open DOISearch in Google Scholar
  39. 39. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, et al. Brentuximab vedotin (SGN-35) in patients with relapsed/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation. [ASH Annual Meeting Abstracts].2012;Abstract 2743.
    Open DOISearch in Google Scholar
  40. 40. Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study.2013;1348-56.
    Open DOISearch in Google Scholar
  41. 41. Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.2012;2283-6.
    Open DOISearch in Google Scholar
  42. 42. Jalan P, Mahajan A, Pandav V, Bekker S, Koirala J. Brentuximab associated progressive multifocal leukoencephalopathy.2012;1335-7.
    Open DOISearch in Google Scholar
  43. 43. Urru SA, Mariotti E, Carta P, Massidda S, Marcias M, Murru R, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report.2014;9-11.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0036 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 315 - 319
Submitted on: Jul 15, 2015
Accepted on: Aug 16, 2015
Published on: Nov 27, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Hodgkin lymphoma,
relapsed and refractory,
new treatment option,
treatment effectiveness,
toxicity
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Barbara Jezersek Novakovic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 4 (December 2015)
Next article